THE OPIOID BACKLASH
Newsweek US|May 12, 2023
PATIENTS WITH LEGITIMATE MEDICAL NEEDS ARE LOSING ACCESS TO OPIOIDS WHILE ADDICTION AND OVERDOSE RATES CONTINUE TO CLIMB
David H. Freedman
THE OPIOID BACKLASH

DANNY BARCELONA LIVES IN constant fear that doctors will stop the medications he considers lifesaving. The 66-year-old has suffered for more than two decades with a debilitating nervous system disorder and severe back and shoulder pain, forcing him to close his once-thriving dental-lab business in Asheville, North Carolina, and sometimes leaving him bedridden for 18 hours a day. That he can function at all, he says, is due to his ongoing prescription for oxycodone, an opioid.

In the middle of an epidemic of opioid overdoses, doctors, hospitals and pharmacies across America are facing intense pressure to sharply cut back on prescribing and dispensing the drugs. About 8 million patients in the U.S. who depend on opioids to face constant, intense pain are at risk of losing access to the one treatment that seems to make the pain bearable. That includes Barcelona. "I don't think I could have lived without the drugs I've been taking," he says.

The number of opioid prescriptions has plummeted from a high of 251 million in 2010 to well under half that number in 2020-the last year for which figures are available from the U.S. Centers for Disease Control and Prevention (CDC). Yet the number of opioid overdoses has only continued to climb, even as drugs such as buprenorphine that can help overcome addiction and slash the risk of overdose are becoming harder to access than opioids themselves.

The twin problems of patients with a legitimate medical need losing access to opioids, while the addiction and overdose rates swell, add up to a new opioid crisis that may be worse than the original one that emerged at the turn of millennium. Federal and state governments, along with health care, bungled the response to that original crisis, say a range of experts.

This story is from the May 12, 2023 edition of Newsweek US.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the May 12, 2023 edition of Newsweek US.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM NEWSWEEK USView All
AMERICA'S BEST LOYALTY PROGRAMS 2025
Newsweek US

AMERICA'S BEST LOYALTY PROGRAMS 2025

LOYALTY PROGRAMS HAVE BECOME A CORNERSTONE of the modern shopping experience, offering perks and rewards designed to keep customers returning for more.

time-read
3 mins  |
February 21, 2025
Winning the Global Game
Newsweek US

Winning the Global Game

The U.S. holds more cards than China. Whether we keep our strategic advantage depends on how we play our hand

time-read
3 mins  |
February 21, 2025
Solar Power
Newsweek US

Solar Power

Scientists' creation of a record-breaking \"artificial sun\" brings nuclear fusion energy a step closer to being a commercial reality

time-read
2 mins  |
February 21, 2025
Trump vs. Deep State
Newsweek US

Trump vs. Deep State

The president and his efficiency chief Elon Musk have brought in a wave of policies affecting federal employees' jobs. Government workers spoke to Newsweek about the impact

time-read
6 mins  |
February 21, 2025
MAD ABOUT THE GIRL
Newsweek US

MAD ABOUT THE GIRL

AS RENÉE ZELLWEGER REPRISES THE ICONIC CHARACTER, BRIDGET JONES' CREATOR - AND MILLIONS OF FANS, COULDN'T BE HAPPIER

time-read
10+ mins  |
February 21, 2025
Armed and Dangerous
Newsweek US

Armed and Dangerous

A Ukrainian colonel reveals how North Korean soldiers compared with their Russian allies

time-read
4 mins  |
February 21, 2025
Patrick Gibson
Newsweek US

Patrick Gibson

WHEN YOU TAKE ON A ROLE THAT SOMEBODY ELSE MADE FAMOUS, IT'S not easy.

time-read
2 mins  |
February 21, 2025
The AI Will See You Now
Newsweek US

The AI Will See You Now

A light-hearted study into artificial intelligence's ability to perform cognitive tasks has raised questions around the roles of AI and doctors in health care

time-read
6 mins  |
February 21, 2025
Jasmin Savoy Brown
Newsweek US

Jasmin Savoy Brown

SHOWTIME'S YELLOWJACKETS IS REALLY TWO shows in one.

time-read
2 mins  |
February 21, 2025
BIOTECH: Blood, Sweat and Tears
Newsweek US

BIOTECH: Blood, Sweat and Tears

Nine years in the making, Truvian's quick tabletop blood test promises to deliver where Theranos famously couldn't

time-read
6 mins  |
February 14, 2025